JGB1741 是一种有效的选择性 SIRT1 抑制剂，IC50 为 15 μM。 JGB1741 调节 Bax/BCL2 比率、细胞色素 c 释放和 PARP 裂解并增加乙酰化 p53 水平，导致 p53 介导的细胞凋亡。 JGB1741可用于乳腺癌研究。

JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.

JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression[1].

1256375-38-8

C27H24N2O2S

440.56

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years